BSX
Boston Scientific CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted operating margin non-GAAP | 28% | Q1 2026 call | — |
| Asia Pacific operational sales growth non-GAAP | 12% | Q1 2026 call | — |
| Cardiac Rhythm Management sales growth | -3% | Q1 2026 call | — |
| Cardiovascular organic sales growth non-GAAP | 11% | Q1 2026 call | — |
| Endoscopy organic sales growth non-GAAP | 7% | Q1 2026 call | — |
| EP global organic sales growth non-GAAP | 22% | Q1 2026 call | — |
| EP international organic sales growth non-GAAP | 30% | Q1 2026 call | — |
| EP U.S. organic sales growth non-GAAP | 18% | Q1 2026 call | — |
| Europe, Middle East, Africa operational sales growth non-GAAP | 1% | Q1 2026 call | — |
| Interventional Oncology organic sales growth non-GAAP | 15% | Q1 2026 call | — |
| Neuromodulation organic sales growth non-GAAP | 15% | Q1 2026 call | — |
| total company organic sales growth non-GAAP | 9.4% | Q1 2026 call | — |
| U.S. operational sales growth non-GAAP | 11% | Q1 2026 call | — |
| Urology organic sales growth non-GAAP | 1% | Q1 2026 call | — |
| Vascular Therapies organic sales growth non-GAAP | 7% | Q1 2026 call | — |
| WATCHMAN organic sales growth non-GAAP | 19% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BSX
this stock
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
EW
Edwards Lifesciences Corp
|
$53.09B | +8.2% | +11.5% | 49.1 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BSX | -0.8% | -7.4% | -50.3% | +4.9% | -53.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.2% | -11.5% | -59.3% | +3.8% | -63.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.